Quest Diagnostics (DGX) Tops Q3 EPS by 58c, Raises FY Guidance

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $4.31, $0.58 better than the analyst estimate of $3.73. Revenue for the quarter came in at $2.79 billion versus the consensus estimate of $2.73 billion.

GUIDANCE:

Quest Diagnostics sees FY2020 EPS of $9.00-$10.00, versus the consensus of $8.71. Quest Diagnostics sees FY2020 revenue of $8.8-9.1 billion, versus the consensus of $8.74 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight